Home » Topics » BioWorld Science

BioWorld Science
RSS

Novel tau tubulin kinase 1 inhibitors reduce tau phosphorylation in vivo

July 6, 2021

Venadaparib shows safety and preliminary efficacy in first-in-human trial

July 6, 2021

Mersana starts phase I/II umbrella study of XMT-1536 in high-grade serous ovarian cancer

July 6, 2021

Enrollment ongoing in phase I/II study of PVSRIPO

July 6, 2021

DPP3 is a marker of severity in heart failure

July 5, 2021

Transcenta reports antitumor responses with TST-001 in gastric cancer

July 5, 2021

Initiation of phase II study of HA-121-28 in advanced biliary tract cancer

July 5, 2021

SHR-1314 studied in phase II/III trial for active ankylosing spondylitis

July 5, 2021

Phase Ib data presented for ulixertinib plus palbociclib in advanced solid tumors

July 5, 2021

GNT-0003 restores UGT1A1 expression in patients with Crigler-Najjar syndrome

July 5, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...